The Rheumatologist
COVID-19 News
You are here: Home / Articles / FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

FDA Approves Denosumab for Glucocorticoid-Induced Osteoporosis

• By

References

  1. Amgen Inc. News release: FDA approves Prolia (denosumab) for glucocorticoid-induced osteoporosis. 2018 May 15.
  2. Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018 Apr 6. pii: S2213-8587(18)30075-5. [Epub ahead of print]

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »